DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

Yeztugo, a twice yearly injection, offers a promising advancement in HIV prevention, but high costs and insurance uncertainties may limit its accessibility.

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...

Trouble With Existing Options. There are many reasons people living with HIV haven't been able to start any of the 11 currently available single-tablet options, including drug resistance ...

The injectable HIV-1 capsid (viral protein shell) inhibitor needs to be injected once every six months. That’s far less than existing preventative HIV medications that need to be taken daily.

Californians, starting next year, will be able to access HIV prevention medications without a prescription. Gov. Gavin Newsom signed a bill into law on Monday, making California the first state in ...

It is a pill ingested once a day for 28 days. Lenacapavir : This injectable drug has been tested in clinical trials as a potential PrEP therapy. The FDA is scheduled to vote on its approval on ...

A June stu d y estimated as many as 2.2 million Americans could benefit from HIV prevention medications. Men account for nearly 80% of new cases, mostly involving gay or bisexual men, the CDC said.

Gilead’s chairman and CEO, Daniel O’Day, suggested in a statement Wednesday that the drug could “end the HIV epidemic once and for all.” It was approved after astounding results in Gilead ...

The drug, lenacapavir, will be sold under the name Yeztugo. “This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in a press release .